Disclosed is a stable pharmaceutical formulation comprising: an antibody at a concentration of from 5 mg/ml to 150 mg/ml that binds specifically to human angiopoietin 2 (human Ang-2), wherein the antibody comprises a heavy chain variable region (HCVR) having the amino acid sequence of SEQ ID NO:18 and a light chain variable region (LCVR) having the amino acid sequence of SEQ ID NO:20 histidine at a concentration of from 5 mM to 15 mM polysorbate at a concentration of from 0.1 % w/v to 0.3% w/v and (iv) sucrose at a concentration of from 3% w/v to 20% w/v, wherein the formulation has a pH of from 5.5 to 6.5.
